News

12 categories now open for entry, to acknowledge excellence across the field of neuro-rehab

Partnership with the Liverpool Philharmonic to benefit patients, families and staff

Luke Griggs, chief executive of Headway, outlines his thoughts about the ABI Strategy and what it must address; the urgent need for provision for brain injury; and the importance of Headway groups across the country and why their life-changing work must be properly funded "An effective ABI Strategy needs funding" That is the message from Luke Griggs, chief executive of Headway, who admits to having “real fear” around the funding of proper provision through the Strategy, the kind which will truly make a positive impact on the lives of those who need it.  Read our in-depth feature in full by signing up to NR Times below.

By Neil Bindemann, neuroimmunologist and founder of the Person-Centred Neurosciences Society. It was in 2004 when the Primary Care Neurology Society (P-CNS) was established, with one of the main objectives being: to support the education of primary care health professionals to ensure people with suspected neurological conditions receive appropriate and timely specialist care. While today, [...]

A first-of-its-kind technology is boosting the benefit of physical therapy for MS patients through electrical pulses that aim to ‘rewire’ the brain and activate neural pathways. Physical therapy is an essential aspect of treating MS, but it has its limitations. In most cases, MS affects the cerebellum, also known as the brain stem. Physical therapy [...]

NR Times Issue 27 is out now. In this issue, Manchester Arena bombing survivor Martin Hibbert tells us about his mission to be a catalyst for change. Martin was left paralysed after sustaining a severed spinal cord and is using his traumatic experience to change the reality for fellow spinal cord injured people. Martin tells [...]

Clinical neuropsychologist and boxing coach delivering strong outcomes for youth participants

NR Times speaks to UCLA researcher Dr Kevin Patel about the potential of metformin in MS care and an upcoming human trial assessing its efficacy.

Mindful of Huntington's campaign shines a light on the need for greater awareness of HD's 'hidden' symptoms